Parainfluenza Clinical Trials

Find Parainfluenza Clinical Trials Near You

Randomized, Double-blind, Phase 2 Clinical Trial Controlled With Conventional Bacillus Calmette-Guérin (BCG) Vaccine to Evaluate the Safety and Immunogenicity of a Recombinant BCG Vaccine That Expresses the Respiratory Syncytial Virus (RSV) Nucleoprotein (N) (rBCG-N-RSV) in Adults Over 60 Years of Age.

Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 60
Healthy Volunteers: t
View:

• Has completed the written informed consent process.

• Males or females, over 60 years of age as of the date of signature of the informed consent form.

Locations
Other Locations
Greece
Sotiria Thoracic Diseases Hospital of Athens
RECRUITING
Athens
Contact Information
Primary
Maria Moukouli
m.moukouli@pharmassist-cro.com
+30 210 6560700
Backup
Maria Kiriakaki
m.kiriakaki@pharmassist-cro.com
+30 210 6560700
Time Frame
Start Date: 2026-09-14
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 200
Treatments
Experimental: rBCG-N-RSV vaccine
rBCG-N-RSV is a live-attenuated vaccine of Mycobacterium bovis bacillus Calmette-Guerin (BCG) modified to heterologously and constitutively express the RSV nucleoprotein (N). The clinical formulation with this bacterium has been produced under strict quality and safety standards using current Good Manufacturing Practices (cGMP) in the United States of America (USA).~Pharmaceutical form: Lyophilisate for solution for injection~Medicinal product characteristics: Immunological~Route of administration: Intradermal use~Maximum duration of treatment: 1 Day~Maximum daily dose allowed: 0.1~Daily dose unit of measure: CFU/ml colony forming unit(s)/millilitre~Maximum total dose allowed: 0.1~Total dose unit of measure: CFU/ml colony forming unit(s)/millilitre
Active_comparator: Mycobacterium bovis bacillus Calmette-Guerin (BCG)
BCG is a cryo-lyophilized vaccine of an attenuated strain of Mycobacterium bovis BCG, used for active immunization against tuberculosis. It is currently administered in numerous countries worldwide according to national immunization plans.~Medicinal product characteristics: Immunological~Route of administration: Intradermal use~Maximum duration of treatment: 1 Day~Maximum daily dose allowed: 0.1~Daily dose unit of measure: CFU/ml colony forming unit(s)/millilitre~Maximum total dose allowed: 0.1~Total dose unit of measure: CFU/ml colony forming unit(s)/millilitre
Related Therapeutic Areas
Sponsors
Collaborators: Sotiria Thoracic Diseases Hospital of Athens, Pharmassist Ltd, Hellenic Pasteur Institute
Leads: Biothervax SpA

This content was sourced from clinicaltrials.gov